**OriGene Technologies, Inc.**
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

# Product datasheet for TP727094

## CD229 (LY9) Human Recombinant Protein

### Product data:

| | |
|---|---|
| **Product Type:** | Recombinant Proteins |
| **Description:** | Recombinant Human T-lymphocyte Surface Antigen Ly-9/SLAMF3/CD229 (C-6His) |
| **Species:** | Human |
| **Expression cDNA Clone or AA Sequence:** | Lys48-Lys454 |
| **Tag:** | C-His |
| **Buffer:** | Lyophilized from a 0.2 um filtered solution of PBS, pH 7.4. |
| **Note:** | Recombinant Human T-lymphocyte Surface Antigen Ly-9 is produced by our Mammalian expression system and the target gene encoding Lys48-Lys454 is expressed with a 6His tag at the C-terminus. |
| **Stability:** | 12 months from date of despatch |
| **Locus ID:** | 4063 |
| **UniProt ID:** | Q9HBG7 |
| **Summary:** | SLAMF3 (CD229) is a type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family. Mature human SLAMF3 consists of a 407 amino acid (aa) extracellular domain (ECD) with two Ig-like V-set and two Ig-like truncated C2-set domains. The ECD of human SLAMF3 shares 57% - 59% aa sequence identity with mouse and rat SLAMF3. Within the first two Ig-like domains that are common to all SLAM proteins, human SLAMF3 shares 24% - 39% aa sequence identity with human 2B4, BLAME, CD2F-10, CD84, CRACC, NTB-A, and SLAM. It is expressed on T and B cells, thymocytes, and more weakly on NK cells. It may participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A. SLAMF3 may be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. It also disable autoantibody responses and inhibit IFN-gamma secretion by CD4+ T-cells and negatively regulate the size of thymic innate CD8+ T-cells and the development of invariant natural killer T (iNKT) cells. |

View online »